Alfama

The company has produced hundreds of CORMs and achieved excellent results in various animal models of chronic and acute human diseases. CORMs have the potential to expand CO-based therapies to a wide range of high-value indications, which can be administered orally or intravenously, offering a very attractive therapeutic window and safety profile. After acquiring hemoCORM Ltd. based in London, UK, Alfama began to control various patents and patent applications related to CORMs, making the company an undisputed leader in CORM technology.